๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› China
Clinical trial register · China

Studies with a Chinese investigative site

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the register
Recruitment status
Phase
Lead sponsor
Sun Yat-sen University490 Fudan University472 Second Affiliated Hospital, Zhejiang University, School of Medicine404 Peking Union Medical College Hospital282 Ruijin Hospital281
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to
19052 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
Vebreltinib for Neoadjuvant in METex 14 Skipping Mutant Stage IIA-IIIB (N2) Non-small Cell Lung Cancer (NSCLC)
NCT07156604NSCLC, Neoadjuvant Therapy
Fudan University
Phase 2
30
Shanghai
2025-09-30
Not yet open
A Study of CAR-T Cells in Subjects With Autoimmune Diseases
NCT07040917Autoimmune Diseases
Chinese PLA General Hospital
Phase EARLY_PHASE1
12
Beijing
2025-09-30
Recruiting
A Study to Learn How Safe AZD6621 is, How Well it Works, and How it Moves Throughout the Body Over Time, in Adult Male Participants With Metastatic Prostate Cancer
NCT07192614Prostate Cancer
AstraZeneca
Phase 1/2
52
Beijing, Chengdu, Guangzhou, Nanjing
2025-09-30
Not yet open
A Phase 3 Study of HS-20094 in Patients With T2DM Inadequately Controlled With Diet and Exercise Alone
NCT07156500Type 2 Diabetes
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Phase 3
204
Beijing
2025-09-30
Not yet open
Mazdutide as Adjuvant Therapy Following Sleeve Gastrectomy in Severe Obesity
NCT07135141Severe Obesity
Beijing Friendship Hospital
Not applicable
256
Beijing, Changsha, Chengdu, Guangzhou, Jinan, Kunming, Nanjing, Shanghai
2025-09-30
Not yet open
YOLT-204 in Patients With Hemoglobinopathies
NCT07190001Hemoglobinopathies (Transfusion-dependent ฮฒ-thalassemia and Sickle Cell Disease)
Guangzhou Women and Children's Medical Center
Phase EARLY_PHASE1
18
Guangzhou
2025-09-30
Recruiting
Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy
NCT07106762Urothelial Cancer
Bristol-Myers Squibb
Phase 2/3
470
Beijing, Fuzhou, Xiamen, Guangzhou, Zhengzhou, Changsha, Nanjing, Nantong
2025-09-30
Recruiting
Vebreltinib for Advanced or Metastatic CCS
NCT07153887Clear Cell Sarcoma (CCS)
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 2
30
Hangzhou
2025-09-30
Recruiting
A Study of MHB036C Combined With MHB039A in Patients With Advanced Breast Cancer or Other Advanced Malignant Solid Tumors
NCT07130383Advanced Breast Cancer, Advanced Malignant Solid Tumor
Minghui Pharmaceutical (Hangzhou) Ltd
Phase 2
210
Shanghai
2025-09-30
Recruiting
Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer
NCT07022483Endometrial Cancer
Daiichi Sankyo
Phase 3
710
Beijing, Changchun, Chengdu, Hangzhou, Jinan, Linyi, Nanchang, Nanning
2025-09-30
Not yet open
Dynamic Breath VOC Profiling as a Non-invasive Tool to Assess Hemodialysis Adequacy
NCT07189741Uremia, Uremia; Chronic, Hemodialysis
Second People's Hospital, Shanghai
Observational
50
Shanghai
2025-09-30
Not yet open
A Phase 3 Study of HS-20094 in Patients With T2DM
NCT07156539Type 2 Diabetes
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Phase 3
546
Jinan, Tianjin
2025-09-30
Not yet open
SHR2554 Combined With Endocrine Therapy in Advanced Breast Cancer
NCT07125950Advanced Breast Cancer
Henan Cancer Hospital
Phase 2
60
Zhengzhou
2025-09-30
Not yet open
Anti-CD19 Chimeric Antigen Receptor T Cells for Refractory Autoimmune Diseases
NCT07161193Autoimmune Diseases
Hebei Senlang Biotechnology Inc., Ltd.
Phase 1/2
30
Luoyang
2025-09-30
Recruiting
LDRT Combined With Pucotenlimab and Standard Therapy for Advanced Pancreatic Cancer: A Single-Arm Study
NCT07312422Pancreatic Cancer, PD-L1, PD-1 Inhibitor, LDRT
Zhejiang Provincial People's Hospital
Phase 1/2
10
Hangzhou
2025-09-30
Not yet open
Adebrelimab Plus Chemoradiotherapy Followed by Adebrelimab Maintenance in Limited-Stage SCLC
NCT07200154Limited-stage Small-cell Lung Cancer, Concurrent Chemoradiation Therapy
Peking University Cancer Hospital & Institute
Phase 2
30
Beijing
2025-09-30
Recruiting
Study of MT1013 for the Treatment of Patients With Secondary Hyperparathyroidism
NCT07122401Secondary Hyperparathyroidism, Chronic Kidney Disease
Shaanxi Micot Pharmaceutical Technology Co., Ltd.
Phase 3
424
Shanghai
2025-09-30
Active, closed
A Study of SH3765 Tablets in Combination With Fulvestrant in Patients With HR+/HER2- Advanced Breast Cancer.
NCT07557004HR+ / HER2- Advanced Breast Cancer
Nanjing Sanhome Pharmaceutical, Co., Ltd.
Phase 1
30
Hefei
2025-09-30
Recruiting
The Efficacy and Safety of Pregabalin Combined With Dexmedetomidine in Patients With Fibromyalgia
NCT07230197Fibromyalgia, Pregabalin, Dexmedetomidine
Beijing Tiantan Hospital
Not applicable
400
Beijing
2025-09-30
Not yet open
Mechanistic Studies of Chronic COPD Using Single-Cell Sequencing and Single-Cell Spatial Transcriptomics
NCT07208123COPD
Tongji University
Observational
150
Shanghai
2025-09-30
Recruiting
Efficacy and Safety of Transcutaneous Auricular Vagus Nerve Stimulation for Postoperative Headache Following Stent-Assisted Coiling of Unruptured Intracranial Aneurysms
NCT07479082Unruptured Intracranial Aneurysm, Headache, Vagus Nerve Stimulations
Beijing Tiantan Hospital
Not applicable
440
Beijing
2025-09-30
Recruiting
A Bidirectional Cohort Study on Prophylactic Resection Surgery in Populations at Moderate-to-High Risk for Hereditary Ovarian Cancer
NCT07532434Ovarian Cancer, Breast Cancer
Peking University Third Hospital
Observational
480
Beijing
2025-09-30
Recruiting
The Efficacy and Safety of Pregabalin and Crisugabalin in Patients With Fibromyalgia
NCT07196657Fibromyalgia, Pregabalin, Pain
Beijing Tiantan Hospital
Not applicable
1,116
Beijing
2025-09-30
Not yet open
EDN Combined With TACE/HAIC and Second-Line Immune-Targeted Treatment Versus TACE/HAIC Alone in Locally Advanced HCC With Portal Vein Tumor Thrombosis After First-Line Therapy Failure: A Prospective, Multicenter, Randomized Controlled Trial
NCT07187284HCC - Hepatocellular Carcinoma
Zhongda Hospital
Phase 1/2
62
Nanjing
2025-09-30
Recruiting
A Real-world Prospective Observational Study on the Efficacy and Safety of L-AmB(Liposomal Amphotericin B) for br- IFD(Breakthrough Invasive Fungal Disease) in Children and Adolescent Patients With Hematological Malignancies Receiving Triazoles or Echinocandins Prophylaxis
NCT07357038Fungal Disease
Institute of Hematology & Blood Diseases Hospital, China
Observational
38
Tianjin
2025-09-30
Recruiting
A Trial for Minimally Invasive Neurosurgery With AI-assisted Robotic Guidance for Moderate Basal Ganglia Hemorrhage (RAINBOW-MBH)
NCT06465719Basal Ganglia Hemorrhage
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
330
Hangzhou
2025-09-30
Recruiting
A Study of A-CAR028 Treatment in Subjects With Relapsed or Refractory Acute Myeloid Leukemia
NCT07198867Acute Myeloid Leukemia (AML), CAR-T Cell Therapy
First Affiliated Hospital of Zhejiang University
Phase 1
20
Hangzhou
2025-09-30
Recruiting
Dose-Ranging Study of LQ036 Single-Domain Antibody Nebulization Solution in Poorly Controlled Asthma
NCT07589439Asthma
Shanghai Novamab Biopharmaceuticals Co., Ltd.
Phase 2
216
Shanghai
2025-09-30
Not yet open
A Clinical Study on the Use of a Domestically Produced Three-dimensional Cardiac Electrophysiological Mapping System Combined With Pressure Monitoring Technology and Star Mapping Technology for the Treatment of Paroxysmal Atrial Fibrillation.
NCT07039032Paroxysmal Atrial Fibrillation (PAF)
Shanghai MicroPort EP MedTech Co., Ltd.
Not applicable
20
Chengdu
2025-09-30
Recruiting
SKB264 Plus Inetetamab in HER2-Positive Metastatic Breast Cancer Patients Progressing After T-DXd Treatment
NCT07182721HER2-positive, Unresectable, Locally Advanced or Metastatic Breast Cancer, SKB264, Inetetamab
Fudan University
Phase 2
48
Shanghai
2025-09-30
Recruiting
Immune Profiling of Refractory cSLE Exposed to CD3ร—CD19 BiTE
NCT07352332Childhood-onset Systemic Lupus Erythematosus
The Children's Hospital of Zhejiang University School of Medicine
Observational
6
Hangzhou
2025-09-30
Recruiting
RAINBOW-ICH Trial of AI Guided Minimally Invasive Neurosurgery for ICH
NCT07205263Basal Ganglia Hemorrhage, Intraventricular Hemorrhage, Brainstem Stroke, Intracranial Hemorrhage, Spontaneous
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
1,000
Hangzhou
2025-09-30
Recruiting
Evaluation of Efficacy, Safety, and Tolerability of Povetacicept in Participants With Primary Membranous Nephropathy (pMN)
NCT07204275Primary Membranous Nephropathy
Vertex Pharmaceuticals Incorporated
Phase 2/3
176
Baotou, Beijing, Bengbu, Changchun, Changsha, Chengdu, Dalian, Dongguan
2025-09-30
Recruiting
Trial of CS060380 Tablets for Non-alcoholic Steatohepatitis (NASH)
NCT07198386NASH
Cascade Pharmaceuticals, Inc
Phase 2
120
Fuzhou, Xiamen, Suzhou, Shanghai, Hangzhou, Wenzhou
2025-09-30
Active, closed
A Phase II Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy
NCT07176702Metastatic PDAC, HER2-positive Status
Shanghai Zhongshan Hospital
Phase 2
45
Nanjing, Shanghai
2025-09-30
Recruiting
An Observational Study of Glofitamab in Chinese Adult Participants With 2L Diffuse Large B-Cell Lymphoma
NCT07200375Diffuse Large B-Cell Lymphoma
Hoffmann-La Roche
Observational
300
Langfang, Tianjin, Beijing, Changchun, Chengdu, Guangzhou, Harbin, Jinan
2025-09-29
Recruiting
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
NCT07144280Non-small Cell Carcinoma, Non-Small Cell Lung Cancer Metastatic, Non-Small Cell Lung Carcinoma
Pfizer
Phase 3
680
Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Nanning, Harbin, Wuhan
2025-09-29
Recruiting
A Study of BL-M07D1 vs Pembrolizumab-platinum Chemotherapy in First-line Treatment of HER2-mutant Advanced or Metastatic Non-squamous NSCLC
NCT07178795Non-squamous Non-small Cell Lung Cancer
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 3
440
Guangzhou
2025-09-29
Not yet open
Evaluation of the Efficacy and Safety of Megestrol Acetate in Preventing Nausea and Vomiting Induced by Highly Emetogenic Chemotherapy
NCT07130617Efficacy, Safety, Megestrol Acetate, Adult Subject
Changchun GeneScience Pharmaceutical Co., Ltd.
Phase 1
132
Guangzhou
2025-09-29
Not yet open
A Clinical Study on Alleviating Hemorrhoids-related Symptoms of Pelvic Radiation Therapy
NCT07175584Hemorrhoidal Disease, Cervical Cancer Radiation Complications
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Not applicable
300
Shanghai
2025-09-29
Recruiting
The 90% Effective Ventilation Pressure (EP90) for Esophageal Insufflation Avoidance During Anesthesia Induction
NCT07340255Airway Management, Induction of Anesthesia
Affiliated Hospital of Jiaxing University
Not applicable
60
Jiaxing
2025-09-29
Recruiting
Study of PD-1Ab21-BCMA CAR-T Therapy for Consolidation of Multiple Myelomawith Renal Dysfunction
NCT07489534Multiple Myeloma
Daihong Liu
Phase 2
25
Beijing
2025-09-29
Recruiting
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of RO7837195 in Participants With Moderately to Severely Active Ulcerative Colitis (UC)
NCT06979336Ulcerative Colitis
Genentech, Inc.
Phase 2
224
Fuzhou, Xiamen, Guangzhou, Huizhou, Zhengzhou, Wuhan, Changchun, Binzhou
2025-09-29
Recruiting
Guiding Value of Urinary Tumor DNA Testing in Repeat Transurethral Resection of Non-Muscle-Invasive Bladder Cancer
NCT07187635Bladder Cancer, Liquid Biopsy, Repeat Transurethral Resection of Bladder Tumor
Tianjin Medical University Second Hospital
Not applicable
196
Nanchang, Guangzhou, Xingtai, Kunming, Shanghai, Tianjin
2025-09-28
Recruiting
Iparomlimab and Tuvonralimab Combined With Apatinib and Irinotecan Hydrochloride for the Treatment of Advanced Alpha-fetoprotein-producing Gastric Cancer (AFPGC)
NCT07289997AFP Gastric or Gastroesophageal Junction Adenocarcinoma, PD-1/CTLA-4, AFPGC, Immunotherapy
Hebei Medical University Fourth Hospital
Phase 2
39
Shijiazhuang
2025-09-28
Recruiting
This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naรฏve.
NCT07028853Metastatic Castration Sensitive Prostate Cancer (mCSPC), Hormone Sensitive Prostate Cancer, Prostate Cancer, Cancer of the Prostate
Pfizer
Phase 3
1,000
Wuhu, Beijing, Chongqing, Lanzhou, Guangzhou, Wuhan, Changsha, Huai'an
2025-09-28
Recruiting
QL1706 in the Treatment of Advanced Bone and Soft Tissue Sarcoma
NCT06939855Bone and Soft Tissue Tumors
Sun Yat-sen University
Phase 2
45
Guangzhou
2025-09-28
Active, closed
The Association Between Axillary Lymph Node Metastasis Patterns and Breast Cancer Prognosis
NCT07283718Breast Cancer Invasive
Wenjin Yin
Observational
2,467
Shanghai
2025-09-28
Recruiting
A Study to Assess the Safety of HSK31858 in Participants With Non-Cystic Fibrosis Bronchiectasis
NCT07616375Non-cystic Fibrosis Bronchiectasis
Haisco Pharmaceutical Group Co., Ltd.
Phase 3
669
Yixingcun
2025-09-28
Recruiting
Mazdutide in Type 2 Diabetes With Early-Stage Cognitive Impairment (LIGHT-COG Study)
NCT07083154Dementia, Mild, Mild Cognitive Impairment, Type 2 Diabetes
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 3
420
Changsha, Changzhou, Nanjing, Dalian, Shanghai
2025-09-27
Not yet open
A Phase II Efficacy and Safety Study of HSK44459 in Subjects With Moderate to Severe Plaque Psoriasis
NCT07150988Psoriasis
Haisco Pharmaceutical Group Co., Ltd.
Phase 2
150
Hangzhou
2025-09-26
Recruiting
Serplulimab Combined With Induction Chemotherapy and Radiotherapy in Nasopharyngeal Carcinoma
NCT07177443Locally Advanced Nasopharyngeal Carcinoma
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 3
710
Wuhan
2025-09-26
Recruiting
A 52-week Study of Rilzabrutinib Efficacy and Safety Compared to Placebo in Adults Diagnosed With IgG4-related Disease
NCT07190196Immunoglobulin G4 Related Disease
Sanofi
Phase 3
124
Beijing, Chengdu, Hangzhou, Jiazhuang, Taiyuan, Wuhan, Yantai
2025-09-26
Active, closed
Telitacicept for Refractory Chronic Inflammatory Demyelinating Polyneuropathy
NCT07597733Refractory Chronic Inflammatory Demyelinating Polyneuropathy
Sichuan Academy of Medical Sciences
Not applicable
76
Chengdu
2025-09-26
Recruiting
A Clinical Study Evaluating the Safety and Efficacy of GT801 Injection in Adult Patients With Relapsed/Refractory CD19-positive B-cell Hematologic Malignancies and Autoimmune Hemolytic Anemia
NCT07205315B-cell Acute Lymphoblastic Leukemia (B-ALL), Chronic Lymphocytic Leukemia (CLL), B-cell Non-Hodgkin's Lymphoma (B-NHL), Autoimmune Hemolytic Anemia (AIHA)
Grit Biotechnology
Phase EARLY_PHASE1
28
Zhengzhou, Tianjin
2025-09-26
Recruiting
The Efficacy and Safety of Iparomlimab and Tuvonralimab Injection Combined With Chemotherapy as the First-line Treatment for Esophageal Squamous Cell Carcinoma
NCT07290010Esophageal Squamous Cell Carcinoma (ESCC)
Hebei Medical University Fourth Hospital
Phase 2
25
Shijiazhuang
2025-09-26
Recruiting
B7H3/IL13Ra2 Bispecific Armored Chimeric Antigen Receptor T-Cell Therapy Study for Recurrent/Refractory Glioblastoma
NCT07193628Refractory Glioblastoma, Recurrent Glioblastoma
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 1
14
Hangzhou
2025-09-26
Recruiting
Phase IV Clinical Study of sIPV Administration in Adolescent and Adult Populations
NCT07354269Poliomyelitis
Sinovac Biotech Co., Ltd
Phase 4
180
Dingxi, Lanzhou, Zhangye
2025-09-26
Not yet open
To Evaluate the Safety, Efficacy and Kinetic Characteristics of TRD205 Tablets for Postoperative Analgesia After Unilateral Hip Arthroplasty
NCT07121101Postoperative Analgesia After Unilateral Hip Arthroplasty
Beijing Tide Pharmaceutical Co., Ltd
Phase 2
40
Guangzhou
2025-09-26
Recruiting
Intestinal Low Dose Radiotherapy Combined With Immunotherapy in Immune-resistant Metastatic Malignant Solid Tumors
NCT07071103Radiotherapy, Metastatic Solid Cancers, Immune Checkpoint Blockade, Esophageal Neoplasms Malignant
Chuangzhen Chen
Phase 2
48
Shantou
2025-09-26
Recruiting
Study of Tislelizumab Combined With Chemoradiotherapy and Surgery for Unresectable Esophageal Squamous Cell Carcinoma
NCT07039162Esophageal Squamous Cell Carcinoma (ESCC), Locally Advanced Unresectable Esophageal Cancer
Ming-Yu Lien
Phase 2
45
2025-09-26
Recruiting
Effectiveness of School-Based Time-Restricted Eating for the Prevention and Control of Obesity in Children
NCT07184281Childhood Obesity, Childhood Obesity Pevention
Children's Hospital of Soochow University
Not applicable
1,380
Suzhou
2025-09-26
Active, closed
Immunogenicity and Safety Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered in Healthy Children and Adolescents in China
NCT07135986Meningococcal Infection, Healthy Volunteers
Sanofi
Phase 3
1,602
Nanning, Jingxi, Liuzhou, Tengzhou
2025-09-26
Recruiting
A Clinical Study of Tulisokibart (MK-7240) to Treat Radiographic Axial Spondyloarthritis (MK-7240-013)
NCT07133633Radiographic Axial Spondyloarthritis
Merck Sharp & Dohme LLC
Phase 2
315
Bengbu, Beijing, Guangzhou, Luoyang, Pingxiang, Changchun, รœrรผmqi, Kunming
2025-09-26
Recruiting
Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma
NCT07129993Urothelial Cancer, Bladder Cancer
Daiichi Sankyo
Phase 2/3
630
Beijing, Chengdu, Guangzhou
2025-09-26
Active, closed
A Phase I Clinical Study to Evaluate the PK Profile, Efficacy, Safety and Immunogenicity of HLX17 vs. Keytrudaยฎ in Multiple Resected Solid Tumors
NCT07160335Non-small Cell Lung Cancer, Melanoma, Renal Cell Carcinoma
Shanghai Henlius Biotech
Phase 1
174
Hefei, Wuhu, Beijing, Hunan, Fuzhou, Xiamen, Lanzhou, Cangzhou
2025-09-26
Not yet open
Study of CM355 in Patients With Systemic Lupus Erythematosus
NCT07104344Systemic Lupus Erythematosus
Second Xiangya Hospital of Central South University
Not applicable
5
Changsha
2025-09-25
Recruiting
PA3-17 Injection in Adult Patients With CD7-positive Relapsed/Refractory T-lymphoblastic Leukemia/Lymphoma
NCT07188610CD7-positive Relapsed/Refractory T Lymphoblastic Leukemia/Lymphoma
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Phase 2
100
Hefei, Beijing, Guangzhou, Harbin, Zhengzhou, Wuhan, Nanjing, Suzhou
2025-09-25
Not yet open
Study on the Correlation Between Serum and Fecal Sialic Acid Levels and Tumor Characteristics as Well as Postoperative Anastomotic Leakage in Patients With Colorectal Tumors
NCT07189663Colorectal Neoplasia, Anastomotic Leakage
Xiaolong Li
Observational
1,468
Chongqing
2025-09-25
Recruiting
A Prospective Real-World Observational Study of Nanocrystalline Megestrol Acetate in Patients With Cancer Cachexia
NCT07243379Clinical Characteristics and Treatment Outcomes of Malignant Tumor Cachexia, Multicenter Observational Study
Changchun GeneScience Pharmaceutical Co., Ltd.
Phase 4
495
Zhengzhou
2025-09-25
Recruiting
Clinical Trial of TQC2731 Injection in Patients With Chronic Sinusitis and Nasal Polyps
NCT07107256Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
Phase 3
246
Fuyang, Hefei, Beijing, Chongqing, Xiamen, Lanzhou, Guangzhou, Shenzhen
2025-09-25
Recruiting
An Open-Label, Bayesian Adaptive Phase II Clinical Study in HR+/HER2- Advanced Breast Cancer After Progression on Standard Therapy
NCT07117630Breast Cancer
Fudan University
Phase 2
60
Shanghai
2025-09-25
Recruiting
A Single Ascending Dose of HRS-2162 in Healthy Subjects
NCT07195604Reversal of Neuromuscular Blockade
Fujian Shengdi Pharmaceutical Co., Ltd.
Phase 1
64
Chengdu
2025-09-25
Recruiting
FOLFOX Combined With Durvalumab (MEDI4736), Bevacizumab, and Stereotactic Body Radiotherapy in Sequential Treatment of Potentially Resectable Locally Advanced Hepatocellular Carcinoma
NCT07012798Hepatocellular Carcinoma (HCC)
Tianjin Medical University Cancer Institute and Hospital
Phase 2
30
Tianjin
2025-09-25
Not yet open
A Study of GR1802 Injection in Patients With Seasonal Allergic Rhinitis.
NCT07199257Allergic Rhinitis, Seasonal
Genrix (Shanghai) Biopharmaceutical Co., Ltd.
Phase 3
144
Wuhan
2025-09-25
Not yet open
QL1706 Plus XELOX as Neoadjuvant Therapy for MSS/pMMR Clinical Stage III Colon Cancer
NCT07156682Colon Cancer, MSS/pMMR, QL1706
Qilu Hospital of Shandong University
Phase 2
21
Jinan
2025-09-25
By invitation
Synergistic Effect of Intravenous Lidocaine on Anesthetic Induction and Emergence in Patients Undergoing Laparoscopic Cholecystectomy or Gynecological Surgery
NCT07193836Cholecystectomy, Laparoscopic, Gynecologic Surgical Procedures, Anesthesia and Procedure Related Time Intervals
General Hospital of Ningxia Medical University
Not applicable
195
Yinchuan
2025-09-25
Not yet open
Advancing Assessment for Disorders of Consciousness
NCT07180589Disorders of Consciousness
Xuanwu Hospital, Beijing
Observational
200
Beijing
2025-09-25
Recruiting
Clinical Study of LV009 Injection for the Treatment of Relapsed/Refractory CD19-Positive Hematologic and Lymphoid Malignancies
NCT07312630Non-Hodgkin Lymphoma (NHL), Acute Lymphoblastic Leukemia (ALL), Adult
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Phase EARLY_PHASE1
19
Hefei
2025-09-25
Recruiting
MH-ART vs CF-IMRT in Postoperative Cervical/Endometrial Cancer
NCT07584161Cervical Cancer, Endometrial Cancer
Xiaorong Hou
Not applicable
228
Beijing
2025-09-25
Recruiting
Ruxolitinib Plus Etanercept vs Ruxolitinib for Steroid-Refractory Severe Acute GVHD
NCT07184853Graft vs Host Disease
First Affiliated Hospital of Zhejiang University
Not applicable
122
Hangzhou
2025-09-25
Not yet open
TAS-102 Plus Radiotherapy in Elderly ESCC
NCT07196345ESCC, TAS 102, Radiotherapy
Qianfoshan Hospital
Phase 1/2
45
Jinan
2025-09-25
Active, closed
A Study of IBI3032 in Chinese Participants With Overweight or Obesity
NCT07170319Overweight or Obesity
Innovent Biologics Technology Limited (Shanghai R&D Center)
Phase 1
79
Hefei
2025-09-25
Recruiting
Neoadjuvant Chemotherapy Combined With Sintilimab and Bevacizumab for TNBC (NEOTORCH-BREAST07)
NCT07351487TNBC - Triple-Negative Breast Cancer
First Affiliated Hospital of Zhejiang University
Phase 2
37
Hefei, Shanghai
2025-09-25
Recruiting
Iparomlimab and Tuvonralimab (QL1706) in Patients With HR-positive, HER2-negative Advanced Breast Cancer
NCT07180160Advanced Breast Cancer
Wenjin Yin
Phase 2
123
Shanghai
2025-09-25
Recruiting
JMT106 Injection in the Treatment of Advanced Solid Tumors
NCT07275073Advanced Solid Tumor, Lung Squamous Cell Carcinoma, Hepatocellular Carcinoma
Shanghai JMT-Bio Inc.
Phase 1
200
Zhejiang
2025-09-25
Not yet open
A Comparison of Vorolanib Tablets Combined With Everolimus Versus Sunitinib in Patients With Advanced Renal Cell Carcinoma Who Have Progressed After Treatment With Immunotherapy Monotherapy or in Combination With TKI
NCT07165418Renal Cell Carcinoma (RCC)
Peking University Cancer Hospital & Institute
Phase 3
116
Beijing
2025-09-25
Not yet open
A Prospective Single-Arm Observational Study of Maribavir for the Treatment of Post Hematopoietic Stem Cell Transplantation Cytomegalovirus Infection
NCT07141095Infections, Cytomegalovirus
Institute of Hematology & Blood Diseases Hospital, China
Observational
17
Tianjin
2025-09-25
Not yet open
Effectiveness of Extracorporeal Shockwave Therapy Based on Fascial Manipulation Theory for Lateral Epicondylitis
NCT07131423Lateral Epicondylitis (Tennis Elbow)
ZHANG PENG
Not applicable
123
Nanjin
2025-09-25
Recruiting
The Purpose of This Study is to Evaluate the Efficacy and Safety of 626 in the Treatment of SLE
NCT07185269Systemic Lupus Erythematosus (SLE)
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Phase 1/2
198
Beijing
2025-09-24
Recruiting
"Smart Family Doctor" Assisted Comprehensive Management of Secondary Prevention Among Post Coronary Artery Bypass Graft Patients or Post Percutaneous Coronary Intervention Patients
NCT06615609Post Coronary Artery Bypass Grafting, Hypertension, Diabetes Mellitus, Hyperlipidemia
China National Center for Cardiovascular Diseases
Not applicable
536
รœrรผmqi
2025-09-24
Recruiting
Laparoscopic Partial Splenectomy for Hypersplenism in Liver Cirrhosis Patients
NCT07205471Cirrhoses, Liver, Splenectomy; Status, Partial
Northern Jiangsu People's Hospital
Not applicable
30
Yangzhou
2025-09-24
Recruiting
A Study of BL-M07D1 Versus Investigator's Choice of Chemotherapy in Patients With HER2-positive Locally Advanced or Metastatic Gastric or Gastro-esophageal Junction Adenocarcinoma
NCT07152405Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 3
490
Harbin, Shanghai
2025-09-24
Recruiting
Timing of Anticoagulation After Emergency Endovascular Therapy for Acute Ischemic Stroke With Atrial Fibrillation 2
NCT07139314Ischemic Stroke, Atrial Fibrillation
Capital Medical University
Not applicable
240
Maโ€™anshan, Beijing, Zhangzhou, Heyuan, Qinzhou, Baoding, Harbin, Jiamusi
2025-09-24
Recruiting
A Study of Firsekibart Versus Anakinra in Adult-Onset Still's Disease
NCT07191444Still's Disease, Adult-Onset
Ruijin Hospital
Observational
20
Shanghai
2025-09-24
Recruiting
A Drug-Drug Interaction Study of HDM1002 and Metformin, Empagliflozin, Midazolam, Valsartan, and Warfarin
NCT07331389Overweight Subject, Healthy Subjects
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Phase 1
111
Hefei
2025-09-24
Recruiting
A Phase I/II Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
NCT07123454B-cell Non-Hodgkin Lymphoma
AstraZeneca
Phase 1/2
91
Chengdu, Guangzhou
2025-09-24
Recruiting
Saline Contrast Electrical Impedance Tomography Method for Diagnosis of Acute Pulmonary Embolism
NCT07190079Acute Pulmonary Embolism
Peking Union Medical College Hospital
Observational
343
Beijing
2025-09-24
By invitation
HCL001 Cell Injection for Decompensated Cirrhosis: A Phase I/II Trial
NCT07488546Decompensated Cirrhosis
Shanghai Huicun Medical Technology Co., Ltd.
Phase 1/2
39
Shanghai
2025-09-23
Recruiting
A Study of Osimertinib-based Adaptive Treatment Guided by ctDNA EGFRm+ Monitoring in NSCLC
NCT07058519Locally Advanced or Metastatic EGFRm Non-small Cell Lung Cancer (NSCLC)
Shanghai Chest Hospital
Phase 2
250
Shanghai
2025-09-23
Rows per page Showing 5901–6000 of 19052
Previous 58 59 60 61 62 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site. Derived from ClinicalTrials.gov. Retrieved 23 September 2026. https://priyalifescience.com/clinical-trials-china?page=60

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →
→

Browse trials by condition

Breast Cancer (416) Advanced Solid Tumors (183) Gastric Cancer (183) Colorectal Cancer (179) Hepatocellular Carcinoma (161) Advanced Solid Tumor (159) Solid Tumor (145) Non-Small Cell Lung Cancer (144) Acute Ischemic Stroke (138) Lung Cancer (134) Pancreatic Cancer (132) Non-small Cell Lung Cancer (131) Multiple Myeloma (126) Coronary Artery Disease (111) Prostate Cancer (111)
→

Browse trials by site location

Beijing (5484) Shanghai (3827) Guangzhou (3318) Hangzhou (1812) Wuhan (1343) Chengdu (1291) Nanjing (1193) Changsha (1154) Chongqing (1056) Fuzhou (1018) Tianjin (940) Zhengzhou (921) Hefei (875) Jinan (785) Changchun (641)
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.